Mannkind Corporation

Technovax, Inc.

Marshall L Grant

Grayson Walker Stowell

Paul Menkin

Bryan R Wilson

Joseph J Guarneri

Andrea Leone-Bay

Keith A Oberg

Joseph Sulner

Chad C Smutney

John J Freeman

Kieran Curley

Karine Fabio

Robert A Baughman

Simon R Bruce

Benoit Adamo

P Spencer Kinsey

John M Polidoro

Carl R Sahi

Kelly Sullivan Kraft

George R Martin

Peter Richardson

Jose M Galarza

Enda Kenny

Hector Munoz

Dawn M Carlson

Per Hellstrom

Scott Daniels

Anthony Smithson

Stephanie Greene

Michael Castagna

David Kendall

Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.

Diketopiperazine microparticles with defined specific surface areas

A method for treating obesity associated to Prader Willi Syndrome and/or binge eating is disclosed. The method utilizes a rapid drug delivery system which delivers small molecules and peptides to the lungs by oral inhalation.

Method and composition for treating obesity

An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.

Method of treating hypoglycemia events in diabetes treatment

Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation.

High capacity diketopiperazine microparticles and methods

Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self-assemble into microparticles. The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and excipients can be incorporated into the particles by spray drying a solution containing the components to be incorporated into microcrystalline diketopiperazine particles. In particular, the microcrystalline particle compositions are suitable for pulmonary drug delivery of one or more peptides, proteins, nucleic acids and/or small organic molecules.

Microcrystalline diketopiperazine compositions and methods

Composition and method for reducing hypoglycemia events in diabetes treatment

Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.

Heat-stable dry powder pharmaceutical compositions and methods

Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Types of surface properties that are altered by the disclosed methods include electrostatic properties, hydrophobic properties, and hydrogen bonding properties.

Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents

Growing community of inventors

Newtown, CT, United States of America

Marshall L Grant